Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Cardlytics, Inc. (NASDAQ: CDLX) SEC filings, including current reports on Form 8-K and other regulatory documents filed with the U.S. Securities and Exchange Commission. Cardlytics operates as a commerce media platform in the advertising services sector, and its filings offer detailed insight into financial performance, governance, and material corporate events.
Recent Form 8-K filings from Cardlytics document a range of topics. Some filings furnish earnings press releases that present quarterly results, including GAAP and non-GAAP measures such as Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Loss, and Free Cash Flow. These filings also describe key operating metrics like monthly qualified users (MQUs) and adjusted contribution per user (ACPU), along with management’s discussion of trends and performance.
Other 8-K filings report material corporate actions such as workforce reduction plans under cost-reduction initiatives, amendments to significant agreements with partners, and changes to executive compensation and severance arrangements. Cardlytics has also filed 8-Ks describing the appointment of a Chief Financial Officer and related equity awards and severance protections, providing detail on compensation terms and vesting conditions.
Through these filings, investors can review how Cardlytics manages its capital structure, including disclosures about convertible senior notes, credit facilities, and repayment of debt. The company’s filings also confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the symbol CDLX.
On Stock Titan, users can access Cardlytics’ SEC filings as they are made available from EDGAR, along with AI-powered summaries that help explain the content and implications of complex documents. These tools can assist in understanding Cardlytics’ earnings reports, non-GAAP metrics, insider and executive-related disclosures, and other regulatory information without reading every line of each filing.
Cardlytics, Inc. reported that David Evans has been appointed Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2026. He will replace Alexis DeSieno in these roles, while she continues in a non-officer advisory position through March 6, 2026 to help transition responsibilities.
Evans has prior experience at Cardlytics as CFO and Head of Corporate Development and has also held senior roles in technology-focused investment banking and as CEO of Passport Labs Inc. His compensation includes a $400,000 annual salary, eligibility for a bonus targeted at 100% of base salary, and a grant of 1,000,000 restricted stock units under the Cardlytics Inducement Plan. Half of this equity award vests on February 1, 2027, with the remainder vesting quarterly over the following year, subject to continued service.
He will also receive a $200,000 signing bonus, which must be repaid in full if he leaves voluntarily within 12 months, and a separation arrangement providing 12 months of base salary and continued medical benefits if he is terminated without cause or resigns for good reason.
Cardlytics (CDLX) reported Q3 2025 results showing lower revenue and a large non-cash impairment. Revenue was $52.0 million versus $67.1 million a year ago, reflecting weaker served-based activity while engagement-based revenue grew.
The company recorded $58.8 million of impairment on goodwill and intangible assets, driving an operating loss of $68.9 million and a net loss of $72.7 million for the quarter. Cash and cash equivalents were $43.9 million as of September 30, 2025, with net cash used in operating activities of $3.7 million year-to-date.
On capital structure, Cardlytics fully repaid the remaining $46.1 million of its 2020 convertible notes and had $168.6 million net carrying amount of 4.25% convertible notes due 2029. It also had $46.1 million outstanding on its revolving line of credit. Stockholders’ equity moved to a deficit of $4.7 million, largely due to the impairment. The company recognized a $2.8 million employee retention credit benefit in operating expenses and implemented cost-saving measures, with additional one-time charges expected after quarter-end.
Cardlytics, Inc. (CDLX) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025, and provided details for a conference call to discuss these results and recent corporate highlights. The press release is included as Exhibit 99.1.
The information under Item 2.02 (Results of Operations and Financial Condition) and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. The company listed exhibits under Item 9.01, including the press release and the Inline XBRL cover page.
Cardlytics (CDLX) reported an insider equity change by a director. On October 30, 2025, 6,148 restricted stock units converted into 6,148 shares of common stock, shown with transaction code M (conversion of a derivative security) at a stated price of $0, consistent with RSU settlement.
The RSUs were granted on October 30, 2024 and vested in full one year later. After the settlement, the reporting person holds 6,148 shares with direct ownership. No sales were reported in this filing.
Nick Lynton, Chief Legal & Privacy Officer of Cardlytics, Inc. (CDLX), reported multiple vesting and a sale related to restricted stock units. On 10/01/2025 the reporting person had 10,630, 581 and 1,578 RSUs treated as acquired (each converts into one share) and those awards increased their reported beneficial ownership to 122,425 shares before a sale. On 10/02/2025 the reporting person sold 6,098 shares at a weighted average price of $2.271 (individual sale prices ranged $2.21–$2.36) and the filing shows 116,327 shares owned after the sale. The filing states the sale was made solely to satisfy tax withholding from RSU vesting and discloses original grant sizes and vesting schedules for each RSU award.
Amit Gupta, Cardlytics, Inc. (CDLX) Chief Executive Officer and director, reported vesting and sales tied to restricted stock units. On 10/01/2025 14,350 RSUs vested (each convertible into one share) and were recorded as an acquisition event. To cover tax withholding for that vesting, 7,799 shares were sold on 10/02/2025 at a weighted average price of $2.271, with reported sale prices ranging from $2.21 to $2.36. After these transactions, the Reporting Person beneficially owned 498,310 shares directly and had 28,699 RSU-based shares remaining that will convert to common stock if vesting conditions are met. The original RSU grant totaled 114,796 shares and vests in eight equal installments through 04/01/2026.
Cardlytics, Inc. (CDLX) Form 144 notice shows an insider intends to sell 8,493 shares of common stock, with an aggregate market value of $19,286.75, on or about 10/02/2025 through Fidelity Brokerage Services LLC on NASDAQ. The shares were acquired on 10/01/2025 by restricted stock vesting as compensation. The filer also reported two prior sales in the past three months: 7,324 shares sold on 07/02/2025 for $13,055.76 and 26,048 shares sold on 08/15/2025 for $31,695.21. The filer certifies no undisclosed material adverse information is known.
Cardlytics, Inc. (CDLX) disclosure shows a proposed insider sale of 7,799 common shares through Fidelity Brokerage Services on 10/02/2025 with an aggregate market value of $17,710.75. The shares were acquired on 10/01/2025 upon restricted stock vesting and were granted as compensation. The filing lists total common shares outstanding as 53,236,901. The filer also reported three sales by Amit Gupta in the prior three months: 6,725 shares on 07/02/2025 (gross proceeds $11,987.99), 68,260 shares on 08/18/2025 (gross proceeds $76,806.15), and 68,685 shares on 08/19/2025 (gross proceeds $76,803.57), totaling 143,670 shares and $165,597.71 in gross proceeds. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Cardlytics, Inc. (CDLX) filed a Form 144 reporting a proposed sale of 6,098 common shares acquired on 10/01/2025 via restricted stock vesting. The filing lists an aggregate market value of $13,847.95 and an approximate sale date of 10/02/2025 on NASDAQ. The filer previously sold 5,271 shares on 07/02/2025 for $9,396.09. The form includes the standard representation that the seller does not possess undisclosed material information about the issuer.
Cardlytics, Inc. announced a major cost-reduction plan that includes cutting approximately 90 full-time employees, about 24% of its current workforce. The company expects to record about $2.3 million in one-time charges for severance and related costs, mostly in the quarter ending December 31, 2025.
Management expects the workforce reduction and related cash payments to be substantially complete by the end of that quarter, and notes that actual expenses could differ. Cardlytics may also face additional costs, including possible impairment charges, related to this restructuring.